Immune profiling of lupus miliaris disseminatus faciei and successful management with anti-tumour necrosis factor therapy.
Administration, Intravenous
Chronic Disease
Drug Therapy, Combination
/ methods
Facial Dermatoses
/ genetics
Gene Expression Profiling
/ methods
Granuloma
/ diagnosis
Humans
Immunity, Cellular
/ immunology
Immunohistochemistry
/ methods
Immunosuppressive Agents
/ administration & dosage
Infliximab
/ administration & dosage
Male
Methotrexate
/ administration & dosage
Rosacea
/ diagnosis
T-Lymphocytes
/ immunology
Th1 Cells
/ immunology
Treatment Outcome
Tumor Necrosis Factor Inhibitors
/ administration & dosage
Young Adult
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
08
04
2021
accepted:
12
04
2021
pubmed:
18
4
2021
medline:
30
11
2021
entrez:
17
4
2021
Statut:
ppublish
Résumé
Lupus miliaris disseminatus faciei (LMDF) is a chronic inflammatory dermatosis of unknown aetiology, most often seen in young adults. Although many treatments for LMDF exist, treatment guidelines have not been developed, and response to therapy is generally unpredictable. We present the results of transcriptomic analysis of LMDF lesional skin, which revealed a variety of differentially expressed genes linking LMDF to alterations in innate and adaptive T helper 1 immunity. Immunohistochemical analysis was also performed, identifying similar changes in T-cell immune responses. Given evidence for increased tumour necrosis factor (TNF) pathway activity, our patient, who had previously been refractory to multiple treatments, was initiated on TNF inhibitor therapy with excellent response. This characterization of the LMDF immune response may lead to improved treatment of this condition.
Substances chimiques
Immunosuppressive Agents
0
Tumor Necrosis Factor Inhibitors
0
Infliximab
B72HH48FLU
Methotrexate
YL5FZ2Y5U1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
910-914Informations de copyright
© 2021 British Association of Dermatologists.
Références
Kim WB, Mistry N. Lupus miliaris disseminatus faciei with isolated axillary involvement. J Cutan Med Surg 2016; 20: 153-4.
Al-Mutairi N. Nosology and therapeutic options for lupus miliaris disseminatus faciei. J Dermatol 2011; 38: 864-73.
Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-22.
Chougule A, Chatterjee D, Yadav R et al. Granulomatous rosacea versus lupus miliaris disseminatus faciei - 2 faces of facial granulomatous disorder: a clinicohistological and molecular study. Am J Dermatopathol 2018; 40: 819-23.
Toda-Brito H, Aranha JMP, Tavares ES. Lupus miliaris disseminatus faciei. An Bras Dermatol 2017; 92: 851-3.
Kaushik A, Kumaran MS, Chatterjee D et al. The search for a uniformly effective treatment in patients with lupus miliaris disseminatus faciei. JAMA Dermatol 2020; 156: 841.
Ferguson L, Fearfield L. Topical dapsone gel is a new treatment option for acne agminata. Clin Exp Dermatol 2019; 44: 453-5.
Yin S, Sun L. Case report: a successful combined treatment of severe lupus miliaris disseminatus faciei with oral isotretinoin and methylprednisolone. Dermatol Ther 2020; 33: e13267.
Shimizu A, Funasaka Y, Ueno T et al. Case of lupus miliaris disseminatus faciei associated with marked formation of cysts, successfully treated with intralesional injections of triamcinolone acetonide. J Dermatol 2017; 44: e164-5.
Koike Y, Hatamochi A, Koyano S et al. Lupus miliaris disseminatus faciei successfully treated with tranilast: report of two cases. J Dermatol 2011; 38: 588-92.
Pariser RJ, Paul J, Hirano S et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68: 765-73.
Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther 2015; 28: 158-65.
Peitsch WK, Kemmler N, Goerdt S et al. Infliximab: a novel treatment option for refractory orofacial granulomatosis. Acta Derm Venereol 2007; 87: 265-6.
Janeway CA Jr, Travers P, Walport M et al. Chapter 8. Macrophage activation by armed CD4 TH1 cells. In: Immunobiology: the immune system in health and disease, 5th edn (Austin P, Lawrence E, Gibbs S, eds). New York: Garland Science, 2001. Available at: https://www.ncbi.nlm.nih.gov/books/NBK27153/ (accessed 28 April 2021).
Saito-Sasaki N, Sawada Y, Yamaguchi T et al. A possible role of IL-23/IL-17 axis in patients with lupus miliaris disseminatus faciei. Clin Immunol 2016; 171: 36-7.